Rituximab is an anti-CD20 monoclonal antibody that suppresses inflammation effectively in autoimmune diseases. It was initially approved by the FDA for the treatment of B-cell lymphomas and later ...

CD20 is found on the surface of all normal B cells and on 95% of cancerous B cells. Rituximab, developed in partnership by Roche and Biogen Idec, was the first anti-CD20 monoclonal antibody to be ...

Get detailed information on Rituximab, including pronunciation, uses, dosage guidelines, indications, and instructions on how and when to take it and when to avoid it. The updated prescription ...

Zenyaku Kogyo receives Japanese approval for anti-CD20 monoclonal antibody, Rituxan to treat chronic ITP in children: Tokyo Saturday, November 23, 2024, 10:00 Hrs [IST] Zenyaku Ko ...

Retreatment with rituximab is beneficial ... is complicated by the need for daily injections with a high frequency of injection site reactions. Indirect comparative efficacy studies are fraught ...